Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Current price $0.2173
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Aug 13, 26 |
Daily · Wilder smoothing
| UBS |
| maintain |
| Neutral |
| Neutral |
| Aug 11, 26 | Citigroup | downgrade | Buy | Neutral |
| Jul 24, 26 | Citigroup | maintain | Buy | Buy |
| May 12, 26 | Citigroup | maintain | Buy | Buy |
| May 12, 26 | UBS | maintain | Neutral | Neutral |
| May 12, 26 | Baird | maintain | Outperform | Outperform |
| Feb 20, 26 | Leerink Partners | maintain | Market Perform | Market Perform |
| Jan 9, 26 | Citigroup | maintain | Buy | Buy |
| Nov 3, 25 | UBS | downgrade | Buy | Neutral |
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 16.53 | Oscillator | Buy |
| Stochastic %K (14, 3, 3) | 6.11 | Oscillator | Buy |
| Williams %R (14) | -91.53 | Oscillator | Buy |
| MACD (12, 26, 9) | -0.21 (Hist 0.02) | Oscillator | Buy |
| Average Directional Index (14) | 69.15 (+DI 5.0 / -DI 42.2) | Trend | Strong Sell |
| EMA 20 | 0.41 | MA | Strong Sell |
| SMA 20 | 0.39 | MA | Strong Sell |
| EMA 50 | 0.91 | MA | Strong Sell |
| SMA 50 | 0.80 | MA | Strong Sell |
| SMA 200 | 2.30 | MA | Strong Sell |
Stock news · updated daily
RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the Company) today announced that on October 6, 2026, it received a notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) notifying the Company that it is not in compliance with the NYSE's continued listing standards because the average closing price of the Company's Class A Common Stock (the “Common Stock”) was less than $1.00 per share over a consecutive 30 trading-day period. The Notice does not result in the im.
ACH, ARDX and DPRO have been added to the Zacks Rank #5 (Strong Sell) List on October 9th, 2026.
VLVLY, ACH and CCJ have been added to the Zacks Rank #5 (Strong Sell) List on October 6th, 2026.
Accendra Health, Inc. (NYSE: ACH) (the âCompanyâ) today named Kenneth Gardner-Smith as the Company's next President and Chief Executive Officer. Gardner-Smi
RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the “Company”) today named Kenneth Gardner-Smith as the Company's next President and Chief Executive Officer. Gardner-Smith, who has served on the Company's Board of Directors since March 2022, is expected to assume the role early in the fourth quarter 2026. He will succeed Edward A. Pesicka, who announced his intent to retire in August. Gardner-Smith brings deep experience running large-scale patient care operations and guiding.
BlackRock Inc. acquired a new stake in Accendra Health, Inc. (NYSE: ACH) during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 5,504,102 shares of the company's stock, valued at approximately $18,824,000. BlackRock Inc. owned 7.19% of Accendra Health as of its
RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health (the “Company”) is providing an update on its capital allocation plans and the timeline for the replacement of its chief executive officer. Given recent market conditions, the Company has determined that it is in the best interest of stakeholders not to put in place an at-the-market issuance program. The program was intended to allow the Company to opportunistically issue modest amounts of equity over time, with the proceeds to be used to reduce o.
Square today announced a significant expansion of its Square Credit Card program and a new Square Bill Pay capability that enables sellers to fund vendor paymen
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 10, 2026 | -0.08 | -0.19 | Miss -126.6% | $613.2M |
| May 11, 2026 | -0.06 | -0.04 | Beat 33.3% | $627.8M |
| Feb 19, 2026 | 0.22 | 0.21 | Miss -4.5% | $709.0M |
| Oct 30, 2025 | 0.23 | 0.25 | Beat 8.7% | $697.3M |
| Aug 11, 2025 | 0.27 | 0.26 | Miss -3.7% | $681.9M |
| May 8, 2025 | 0.20 | 0.23 | Beat 15.0% | $2.63B |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| PRE 14A | Oct 19, 2026 | 2026-10-19 17:16:26 | View |
| 8-K | Oct 9, 2026 | 2026-10-09 16:10:18 | View |
| SC 13G | Oct 7, 2026 | 2026-10-07 11:28:32 | View |
| 4 | Oct 6, 2026 | 2026-10-06 20:15:32 | View |
| 8-K/A | Sep 28, 2026 | 2026-09-28 17:06:57 | View |
| 4 | Sep 24, 2026 | 2026-09-24 16:31:35 | View |
| 8-K | Sep 17, 2026 | 2026-09-17 06:35:51 | View |
| 8-K | Aug 17, 2026 | 2026-08-17 06:42:37 | View |
| 8-A12B | Aug 10, 2026 | 2026-08-10 16:20:39 | View |
| 8-K | Aug 10, 2026 | 2026-08-10 16:15:40 | View |
Proxy statement (DEF 14A) disclosures
TTM vs. 5-year historical average (annual ratios)
| Metric | ACH | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -0.1x | 8.1x · sector 20.7x | Discount |
| Forward P/E (FY26E) | 65.2x | EPS est. 0.00 | Discount |
| Price / Book | -0.0x | 1.6x | Discount |
| Price / Sales | 0.0x | 0.2x | Discount |
| EV / EBITDA | 7.8x | 20.2x | Discount |
| Return on equity | 63.4% | — | Top tier |
| Gross margin | 44.8% | 24.4% | Above hist. |
| Debt / Equity | -3.23 | 1.15 | Conservative |
| Piotroski / Altman Z | 2/9 | Z 0.27 | Distress |
Discounted cash flow model
FY2025 · 10-K disclosure
FY2024 · 10-K disclosure
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Oct 5, 26 | Gardner-Smith Kenneth | director, officer: President & CEO | A-Award | 283,554 | — |
| Sep 23, 26 | Leon Jonathan A | officer: EVP & CFO | F-InKind | 4,265 @ $0.85 | $3.63K |
| May 18, 26 | Galloway Heath H | officer: EVP,General Counsel & CorpSecy | F-InKind | 1,822 @ $2.91 | $5.30K |
| May 15, 26 | Leon Jonathan A | officer: EVP & CFO | F-InKind | 1,770 @ $3.04 | $5.38K |
| May 15, 26 | Pesicka Edward A | director, officer: President & CEO | F-InKind | 17,692 @ $3.04 | $53.78K |
| May 15, 26 | Galloway Heath H | officer: EVP,General Counsel & CorpSecy | F-InKind | 966 @ $3.04 | $2.94K |
| May 15, 26 | Bernocchi Perry A | officer: EVP, Chief Operating Officer | F-InKind | 7,908 @ $3.04 | $24.04K |
| May 14, 26 | Kline Teresa L. | director | A-Award | 31,191 | — |